TOP STORIES
respiratory
Medicines

Antifibrotic drug access increasing for Australian IPF patients


Nintedanib and pirfenidone use has grown substantially since their 2017 PBS listing, a sign that more idiopathic pulmonary fibrosis (IPF) patients are getting diagnosed and accessing treatment, an Australian respiratory specialist says. A study of PBS Item Reports for 2017 to...

Nintedanib and pirfenidone use has grown substantially since their 2017 PBS listing, a sign that more idiopathic pulmonary fibrosis (IPF)...

Read more